Skip Navigation
United States Flag

An official website of the United States government. Here's how you know >

A New Look for HHS-OIG. Learn More >>

Change Font Size

Audit (A-02-07-01028)

Review of Medicaid Outpatient Drug Expenditures in the State of New York for the Period October 1, 2003, Through September 30, 2005

Executive Summary

We found that New York claimed Medicaid reimbursement for $1.2 million (Federal share) in fiscal years 2004 and 2005 for outpatient expenditures for drug products that were not eligible for Medicaid coverage. In addition, of the $10.1 billion ($5.2 billion Federal share) in claims submitted by the State for Medicaid reimbursement, $16.2 million (Federal share) represented expenditures for drug products that were not listed on the CMS quarterly drug tape, which lists all covered outpatient drugs. Because the State did not verify whether the drugs missing from the tapes were eligible for Medicaid coverage, these drug expenditures may not be allowable for Medicaid reimbursement. For the remainder of the $10.1 billion ($5.2 billion Federal share) claimed, we identified no other errors.

We recommended that the State (1) refund $1.2 million to the Federal Government for drug expenditures that were not eligible for Medicaid coverage; (2) work with CMS to resolve $16.2 million in payments for drugs that were not listed on the quarterly drug tapes and, therefore, may not have been eligible for Medicaid reimbursement; and (3) strengthen internal controls to ensure that claimed Medicaid drug expenditures comply with Federal requirements. The State generally agreed with our first and second recommendations and agreed with our third recommendation.

Complete Report

Download the complete report (PDF)

Adobe® Acrobat® is required to read PDF files.

Copies can also be obtained by contacting the Office of Public Affairs at 202-619-1343.

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201